420 related articles for article (PubMed ID: 31652460)
21. Dendritic cells can prime anti-tumor CD8
MacNabb BW; Tumuluru S; Chen X; Godfrey J; Kasal DN; Yu J; Jongsma MLM; Spaapen RM; Kline DE; Kline J
Immunity; 2022 Jun; 55(6):982-997.e8. PubMed ID: 35617964
[TBL] [Abstract][Full Text] [Related]
22. Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.
Haug M; Brede G; Håkerud M; Nedberg AG; Gederaas OA; Flo TH; Edwards VT; Selbo PK; Høgset A; Halaas Ø
Front Immunol; 2018; 9():650. PubMed ID: 29670624
[TBL] [Abstract][Full Text] [Related]
23. Cross-presentation of Exogenous Antigens.
Li B; Hu L
Transfus Clin Biol; 2019 Nov; 26(4):346-351. PubMed ID: 30797678
[TBL] [Abstract][Full Text] [Related]
24. Processing and presentation of tumor antigens and vaccination strategies.
van der Bruggen P; Van den Eynde BJ
Curr Opin Immunol; 2006 Feb; 18(1):98-104. PubMed ID: 16343880
[TBL] [Abstract][Full Text] [Related]
25. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
26. Dysfunction of antigen processing and presentation by dendritic cells in cancer.
Bandola-Simon J; Roche PA
Mol Immunol; 2019 Sep; 113():31-37. PubMed ID: 29628265
[TBL] [Abstract][Full Text] [Related]
27. Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy.
Moussion C; Delamarre L
Semin Immunol; 2024 Feb; 71():101848. PubMed ID: 38035643
[TBL] [Abstract][Full Text] [Related]
28. Effective Priming of Herpes Simplex Virus-Specific CD8
Whitney PG; Makhlouf C; MacLeod B; Ma JZ; Gressier E; Greyer M; Hochheiser K; Bachem A; Zaid A; Voehringer D; Heath WR; Wagle MV; Parish I; Russell TA; Smith SA; Tscharke DC; Gebhardt T; Bedoui S
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142130
[TBL] [Abstract][Full Text] [Related]
29. Tumor antigen presentation: changing the rules.
Armstrong TD; Pulaski BA; Ostrand-Rosenberg S
Cancer Immunol Immunother; 1998 Apr; 46(2):70-4. PubMed ID: 9558001
[TBL] [Abstract][Full Text] [Related]
30. Presentation of tumour antigens by dendritic cells and challenges faced.
Robson NC; Hoves S; Maraskovsky E; Schnurr M
Curr Opin Immunol; 2010 Feb; 22(1):137-44. PubMed ID: 20116984
[TBL] [Abstract][Full Text] [Related]
31. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
Front Immunol; 2018; 9():822. PubMed ID: 29755461
[TBL] [Abstract][Full Text] [Related]
32. T Cells as Antigen Carriers for Anti-tumor Vaccination.
Traversari C; Russo V
Methods Mol Biol; 2016; 1393():97-104. PubMed ID: 27033219
[TBL] [Abstract][Full Text] [Related]
33. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
34. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
[TBL] [Abstract][Full Text] [Related]
35. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
[TBL] [Abstract][Full Text] [Related]
36. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
37. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
Saxena M; Bhardwaj N
Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
[TBL] [Abstract][Full Text] [Related]
38. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
39. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
40. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.
Ikeuchi N; Futami J; Hosoi A; Noji S; Kurachi M; Ueha S; Fujii S; Yamada H; Matsushima K; Moriyasu F; Kakimi K
Biochem Biophys Res Commun; 2010 Feb; 392(2):217-22. PubMed ID: 20067764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
